Triple

T2138540
Position Surface form Disambiguated ID Type / Status
Subject Lucentis E46708 entity
Predicate hasGenericName P23148 FINISHED
Object ranibizumab
Ranibizumab is a monoclonal antibody fragment used primarily as an intravitreal injection to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
 E46708 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: ranibizumab | Statement: [Lucentis, hasGenericName, ranibizumab]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: ranibizumab
Context triple: [Lucentis, hasGenericName, ranibizumab]
  • A. Lucentis
    Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
  • B. Avastin
    Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
  • C. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • D. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • E. Taltz
    Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: ranibizumab
Triple: [Lucentis, hasGenericName, ranibizumab]
Generated description
Ranibizumab is a monoclonal antibody fragment used primarily as an intravitreal injection to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: ranibizumab
Target entity description: Ranibizumab is a monoclonal antibody fragment used primarily as an intravitreal injection to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
  • A. Lucentis chosen
    Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
  • B. Avastin
    Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
  • C. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • D. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • E. Taltz
    Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
  • F. None of above.

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a88a174ab48190a5db20c132e5dccf completed March 4, 2026, 7:37 p.m.
NER Named-entity recognition batch_69abbe012aa481909ffa0a50e58efabb completed March 7, 2026, 5:56 a.m.
NED1 Entity disambiguation (via context triple) batch_69ae51b1290c8190a08850b428c99a6c completed March 9, 2026, 4:50 a.m.
NEDg Description generation batch_69ae55923b748190bf7a2df3ae94edc8 completed March 9, 2026, 5:07 a.m.
NED2 Entity disambiguation (via description) batch_69ae55fdc32c8190b6ecdc9b23d64cc5 completed March 9, 2026, 5:09 a.m.
Created at: March 4, 2026, 7:44 p.m.